A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

Official Title

A Phase 2, Single-arm Open-label Study of Combination Nivolumab and Ipilimumab Retreatment in Advanced Renal Cell Carcinoma Patients Progressing on Nivolumab Maintenance Therapy After Nivolumab and Ipilimumab Induction

Summary:

The purpose of the study is to assess the effectiveness of re-induction with Nivolumab combined with ipilimumab.

Trial Description

Primary Outcome:

  • Disease Control Rate (DCR)
Secondary Outcome:
  • Overall Survival (OS)
  • Objective Rate Response Rate (ORR)
  • Duration of Response (DOR)
  • Time to objective Response (TTR)
  • Progression- free survival rate (PFSR)
  • Incidence of adverse events (AEs)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society